Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accounts Payables (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Accounts Payables for 6 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 45.37% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 45.37% year-over-year, with the annual reading at $1.3 million for FY2025, 45.37% down from the prior year.
  • Accounts Payables for Q4 2025 was $1.3 million at Mereo BioPharma, up from $879000.0 in the prior quarter.
  • The five-year high for Accounts Payables was $3.5 million in Q4 2022, with the low at $879000.0 in Q3 2025.
  • Average Accounts Payables over 5 years is $2.3 million, with a median of $2.4 million recorded in 2024.
  • Peak annual rise in Accounts Payables hit 19.1% in 2025, while the deepest fall reached 57.85% in 2025.
  • Over 5 years, Accounts Payables stood at $3.4 million in 2021, then increased by 3.66% to $3.5 million in 2022, then plummeted by 32.82% to $2.3 million in 2023, then increased by 4.01% to $2.4 million in 2024, then plummeted by 45.37% to $1.3 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.3 million, $879000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.